Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy
Edit Porpaczy(Medical University of Vienna), Veronika Sexl(University of Veterinary Medicine Vienna), Jean‐Jacques Kiladjian(Délégation Paris 5), Christoph Kornauth(Munich Leukemia Laboratory (Germany)), Birgit Strobl(University of Veterinary Medicine Vienna), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Sabrina Tripolt(University of Veterinary Medicine Vienna), Emmanuelle Clappier(Centre National de la Recherche Scientifique), Andrea Hoelbl‐Kovacic(University of Veterinary Medicine Vienna), Gregor Hoermann(University of Freiburg), Georg Greiner(Ludwig Boltzmann Institute Applied Diagnostics), Philipp B. Staber(Vienna General Hospital), Ana‐Iris Schiefer(University of Vienna), Thomas Kolbe(Landwirtschaftliche Fachschule Tulln), Harald Herkner(Medical University of Vienna), Gerwin Heller(Medical University of Vienna), Christine Schneckenleithner(Medical University of Vienna), Thomas Decker(Max Perutz Labs), Emilio Casanova(Comprehensive Cancer Center Vienna), Heinz Gisslinger(Medical University of Vienna), Daniela Fux(University of Veterinary Medicine Vienna), Ingrid Simonitsch‐Klupp(Medical University of Vienna), Sabine Fajmann(University of Veterinary Medicine Vienna), Sinan Gueltekin(University of Veterinary Medicine Vienna), Emmanuel Raffoux(Inserm), Cathrin Skrabs(Medical University of Vienna), Michaela Prchal‐Murphy(University of Veterinary Medicine Vienna), Wolfgang R. Sperr(Medical University of Vienna), Bettina Gisslinger(Medical University of Vienna), Klaus G. Schmetterer(Medical University of Vienna), Maria‐Theresa Krauth(Medical University of Vienna), Mathias Mueller(University of Veterinary Medicine Vienna), Eva Maria Putz(University of Veterinary Medicine Vienna), Leonhard Muellauer(Medical University of Vienna), Peter Valent(Medical University of Vienna), Ulrich Jaeger(Medical University of Vienna), Róbert Královics(Medical University of Vienna)
Cited by 155
Related Papers
A Gain-of-Function Mutation of <i>JAK2</i> in Myeloproliferative Disorders
|New England Journal of Medicine|2005|3.5k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
|Journal of Clinical Investigation|2008|1.8k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
|New England Journal of Medicine|2002|1.2k